CD19 and diffuse large B-cell lymphoma: Using a CD19-targeting CAR-T-cell therapy (lisocabtagene maraleucel, initially approved for DLBCL, PMBCL and FL), 45% of patients after multiple disease relapses achieved a complete remission (257).